Patents Assigned to Laboratoire Medidom S.A.
-
Patent number: 9592125Abstract: Disclosed is a device and method which provide a surgical therapy for in situ treatment and repair of intra-articular cartilage lesions and/or defects. The device is an implantable laminate cartilage repair patch which is bio-compatible and physiologically absorbable. The cartilage repair patch has a first outer cell occlusive layer; a second outer, cell porous layer adapted to be disposed proximate a subchondral bone wound site; and a cartilagenic matrix disposed between the first and second layers. The cartilagenic matrix is a sink for diffusion of autologous stem cells and includes chemical components promoting generation of hyaline-like cartilage in the presence of the autologous stem cells. The method of the present invention provides the autologous compositions, which when used in combination with the repair patch provides a therapeutic system to regenerate replacement hyaline-like intraarticular cartilage.Type: GrantFiled: December 21, 2007Date of Patent: March 14, 2017Assignee: Laboratoire Medidom S.A.Inventor: Burkhard Mathies
-
Patent number: 8945609Abstract: The aqueous thermosetting neutralized chitosan composition, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C., comprises 0.1 to 5.0 w/w %, based on the total composition, of a reacetylated chitosan having a molecular weight of not smaller than 100 kDa and a deacetylation degree of 40 to 70%, neutralized with an hydroxylated base, and 1 to 30 w/w %, based on the total composition, of a complexing agent selected from polyoses and polyols derived from polyoses. Said composition is useful for the preparation of an injectable formulation.Type: GrantFiled: December 23, 2005Date of Patent: February 3, 2015Assignee: Laboratoire Medidom S.A.Inventors: Yannic Schuetz, Virginie Caratti-Besson, Oliver Jordan, Robert Gurny
-
Patent number: 8920830Abstract: The present invention relates to wound dressings having a wound contacting layer that contains a wound healing composition and which is adapted to maintain a temperature different from ambient, for example achieve and maintain a heat-absorbing effect on the underlying tissues. The specific physico-chemical structure of the devices of the invention allows fluid containment and absorption of wound secretions while avoiding skin macerations.Type: GrantFiled: July 7, 2009Date of Patent: December 30, 2014Assignee: Laboratoire Medidom S.A.Inventor: Burkhard Mathies
-
Patent number: 8835514Abstract: The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with an hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller than 200 kDa and a deacetylation degree of 30-60%, and may further contain a diol. Said composition may be used as a drug delivery system.Type: GrantFiled: March 22, 2004Date of Patent: September 16, 2014Assignee: Laboratoire Medidom S.A.Inventors: Jérôme Berger, Robert Gurny, Marianne Reist Oechslin
-
Patent number: 8507563Abstract: The composition disclosed is a pseudo-thermosetting neutralized chitosan composition, neutralized with a hydroxylated base, forming a phosphate-free transparent hydrogel at a temperature higher than 5° C. Said composition contains a homogeneously reacetylated chitosan derived from a chitosan having a deacetylation degree of 80-90%, having a molecular weight of not smaller than 200 kDa and a deacetylation degree of 30-60%, and may further contain a diol. Said composition may be used as a drug delivery system.Type: GrantFiled: December 29, 2009Date of Patent: August 13, 2013Assignee: Laboratoire Medidom S.A.Inventors: Jérôme Berger, Robert Gurny, Marianne Reist Oechslin
-
Publication number: 20110311610Abstract: The present invention relates to wound dressings having a wound contacting layer that contains a wound healing composition and which is adapted to maintain a temperature different from ambient, for example achieve and maintain a heat-absorbing effect on the underlying tissues. The specific physico-chemical structure of the devices of the invention allows fluid containment and absorption of wound secretions whilst avoiding skin macerations.Type: ApplicationFiled: July 7, 2009Publication date: December 22, 2011Applicant: LABORATOIRE MEDIDOM S.A.Inventor: Burkhard Mathies
-
Publication number: 20110178035Abstract: A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%.Type: ApplicationFiled: March 29, 2011Publication date: July 21, 2011Applicant: Laboratoire Medidom S.A.Inventors: Stefano Carlino, René-Pierre Bunter
-
Patent number: 7943750Abstract: A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%.Type: GrantFiled: June 18, 2007Date of Patent: May 17, 2011Assignee: Laboratoire Medidom S.A.Inventors: Stefano Carlino, Rene-Pierre Bunter
-
Patent number: 7939655Abstract: A process for preparing a sterile ready-to-use aqueous pharmaceutical formulation comprises a high molecular weight hyaluronic acid salt (HA) at a specified concentration, comprising the steps of: providing an aqueous formulation comprising high molecular weight HA at a concentration of less than the specified final concentration; passing said aqueous formulation through a filter having a pore sizeless than 0.45 pm; concentrating said aqueous formulation by applying a vacuum and boiling off water until said specified concentration is reached.Type: GrantFiled: August 4, 2003Date of Patent: May 10, 2011Assignee: Laboratoire Medidom S.A.Inventor: Stefano Carlino
-
Patent number: 7834173Abstract: The present invention relates to esters of hyaluronic acid with rhein, more particularly to a compound based on hyaluronic acid, wherein alcohol groups of hyaluronic acid are esterified with rhein, to a process for preparing said ester and to a pharmaceutical composition comprising said ester.Type: GrantFiled: February 25, 2005Date of Patent: November 16, 2010Assignee: Laboratoire Medidom S.A.Inventors: Antonello Pietrangelo, Valter Travagli
-
Publication number: 20100136082Abstract: Disclosed is a device and method which provide a surgical therapy for in situ treatment and repair of intra-articular cartilage lesions and/or defects. The device is an implantable laminate cartilage repair patch which is bio-compatible and physiologically absorbable. The cartilage repair patch has a first outer cell occlusive layer; a second outer, cell porous layer adapted to be disposed proximate a subchondral bone wound site; and a cartilagenic matrix disposed between the first and second layers. The cartilagenic matrix is a sink for diffusion of autologous stem cells and includes chemical components promoting generation of hyaline-like cartilage in the presence of the autologous stem cells. The method of the present invention provides the autologous compositions, which when used in combination with the repair patch provides a therapeutic system to regenerate replacement hyaline-like intraarticular cartilage.Type: ApplicationFiled: December 21, 2007Publication date: June 3, 2010Applicant: LABORATOIRE MEDIDOM S.A.Inventor: Burkhard Mathies
-
Publication number: 20080312165Abstract: A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%.Type: ApplicationFiled: June 18, 2007Publication date: December 18, 2008Applicant: Laboratoire Medidom S.A.Inventors: Stefano Carlino, Rene-Pierre Bunter
-
Patent number: 7453004Abstract: A process for preparing aloe-emodin from aloin by oxidizing aloin by treatment with an oxygen-containing gas in the presence of an acid. The aloe-emodin may be used for the production of rhein and diacerein by oxidizing aloe-emodin by treatment with a chromium-free oxidizing medium to obtain rhein and purifying the rhein obtained. The rhein may be acetylated to obtain diacerein.Type: GrantFiled: November 11, 2005Date of Patent: November 18, 2008Assignee: Laboratoire Medidom S.A.Inventors: Stefano Carlino, Guido Di Napoli
-
Publication number: 20080125611Abstract: A process for preparing aloe-emodin from aloin by oxidizing aloin by treatment with an oxygen-containing gas in the presence of an acid. The aloe-emodin may be used for the production of rhein and diacerein by oxidizing aloe-emodin by treatment with a chromium-free oxidizing medium to obtain rhein and purifying the rhein obtained. The rhein may be acetylated to obtain diacerein.Type: ApplicationFiled: November 11, 2005Publication date: May 29, 2008Applicant: LABORATOIRE MEDIDOM S.A.Inventors: Stefano Carlino, Guido Di Napoli
-
Patent number: 6953776Abstract: A topical ophthalmic formulation in the form of an aqueous solution comprising a cyclosporin, hyaluronic acid or one of its salts, and polysorbate 80 is described.Type: GrantFiled: November 21, 2003Date of Patent: October 11, 2005Assignee: Laboratoire Medidom S.A.Inventor: Guido Di Napoli
-
Patent number: 6844365Abstract: It is disclosed the use of diacerein or a pharmaceutically acceptable derivative thereof for the manufacture of a pharmaceutical composition for the treatment of psoriasis or diseases associated therewith, such as psoriatic arthritis.Type: GrantFiled: March 2, 2001Date of Patent: January 18, 2005Assignee: Laboratoire Medidom S.A.Inventor: Guido Di Napoli
-
Patent number: 6596764Abstract: The present invention provides a process for treating arthritis utilizing substantially pure diacetylrhein having an aloe-emodin content of less than 20 ppm.Type: GrantFiled: November 10, 1994Date of Patent: July 22, 2003Assignee: Laboratoire Medidom S.A.Inventors: Alfons Carcasona, Wolf Grimminger, Pentti Hietala, Helga Zaeske, Klaus Witthohn
-
Patent number: 6589999Abstract: The aqueous ophthalmic formulation for the treatment and prevention of infections contains ofloxacin as active ingredient and a chitosan having a weight average molecular weight of 500,000-5,000,000 Daltons and a deacetylation degree of 30-90% as solubilizing agent of ofloxacin. Chitosan having a deacetylation degree of 30-90% may be also used for solubilizing ofloxacin suspended in an aqueous media having a substantially neutral pH in any other applications.Type: GrantFiled: May 17, 2001Date of Patent: July 8, 2003Assignee: Laboratoire Medidom S.A.Inventors: Robert Gurny, Olivia Mireille Felt
-
Patent number: 6528465Abstract: An ophthalmic solution with viscosity enhancing and detergent properties for contact lenses, comprising one or more physiologically acceptably viscosity enhancing agents in aqueous solution having a non-Newtonian rheological behaviour, and one or more physiologically acceptable non-ionic surfactants. The non-ionic surfactant may be selected among esters of fatty acids, sorbitan polyoxyethylates (i.e. polysorbates, such as “Tween”), or block copolymers polyoxyethylene-polyoxypropylene (i.e. poloxamers, such as “Pluronic”). The viscosity enhancing agent may be selected among hyaluronic acid or its salts with alkali or alkaline-earth metals, ethers or esters of cellulose, chitosans, gellans, alginates or carboxyvinyl polymers of the kind Carbopolol® (or carbomer).Type: GrantFiled: September 25, 2001Date of Patent: March 4, 2003Assignee: Laboratoire Medidom S.A.Inventor: Amalio Cantoro
-
Patent number: 6455578Abstract: The present invention is directed to aromatic derivatives of formula (I), wherein: R1 is (a), wherein R3 and R4 are selected from between H and OH, provided that R3 and R4 are not simultaneously H, and R2 is H; or R1 and R2 taken together, are (b), wherein R5 is selected from between CH3 and (CH2)5OH, to the iron complexes thereof, and to their use for the preparation of pharmaceutical compositions for the normalization of iron level.Type: GrantFiled: April 30, 2001Date of Patent: September 24, 2002Assignee: Laboratoire Medidom S.A.Inventor: Guido Di Napoli